Company Overview
- Headquarters
- 601 Gateway Blvd Suite 350, South San Francisco CA
- Website
- akerotx.com
- Phone
- (650) 487-6488
- Employees
- 67
- Founded in
- 2017
- Industry
- BioTech/Drugs
Financials & Stats
Revenue
$10B
Who is Akero Therapeutics
Akero Therapeutics is a clinical-stage company based in South San Francisco, California. With 67 employees, the company focuses on developing innovative treatments for cardio-metabolic diseases. Akero Therapeutics specializes in researching and developing transformational therapies for non-alcoholic steatohepatitis (NASH), a serious liver disease currently lacking approved treatments. Their lead product candidate, efruxifermin (EFX), is a novel engineered Fc-FGF21 fusion protein currently undergoing a Phase 2b clinical trial to assess its potential as a NASH treatment. The company's commitment to NASH patients is underscored by their dedication to developing groundbreaking therapies for this unmet medical need. Akero Therapeutics' innovative approach to drug development holds promise for transforming the treatment landscape for NASH patients. For more information about Akero Therapeutics and their research, please visit their website at akero tx.com.
Company Leadership
Akero Therapeutics Tech Stack
Companies Similar to Akero Therapeutics
Analyze industry trends and opportunities by examining competitors and companies comparable to Akero Therapeutics, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 10M | 18 | Arizona City, AZ | 1998 | |
| 10M | 9 | San Diego, CA | ||
| 10M | 6 | Campbell, CA | 2011 | |
| 10M | 2 | Torrington, WY | ||
| 10M | 1 | San Diego, CA | 2016 |